Immunovant Inc IMVT 深 滬
已收盤 02-06 16:00:00 美东时间
27.05
+2.990
+12.43%
華盛通- 最 高27.345
- 今 開26.88
- 成交量 331.34万股
- 最 低 24.85
- 昨 收 24.06
- 總市值 54.50亿
- 52周最高 27.80
- 市盈率 靜 --
- 換手率 1.64%
- 52周最低 12.72
- 委 比 -57.88%
- 總股本 2.01亿
- 歷史最高 53.75
- 量 比 2.07
- 振 幅 10.37%
- 歷史最低 3.145
- 每 手 1
- 風險率 4.08%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多电话会总结 ｜ Immunovant(IMVT)2025财年Q2业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Immunovant业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **现金状况：** 截至季度末，公司持有44亿美元现金及现金等价物，资产负债表上无债务负担，为当前研发管线提供充足资金支持，并授权高达5亿美元的资本回报计划。 **经营亏损：** 本季度持续经营业务税后净亏损为1.66亿美元。 **股本结构：** 股份数量反映了过去18个月内进行的大规模股份回购计划的影响。 ## 2. 财务指标变化 **现金管理：** 公司维持强劲的现金头寸，预计现有资金足以支撑研发管线直至实现盈利，同时支持管线扩张和额外资本回报。 **债务水平：*
今天 12:08
Immunovant shares are trading higher after the company reported a Q3 EPS beat.
Immunovant shares are trading higher after the company reported a Q3 EPS beat.
今天 00:10
财报速睇 | Immunovant Inc 2025财年Q4营收0.00亿美元，同比持平；归母净利润亏损1.11亿美元，同比亏损缩窄0.4%
华盛资讯2月6日讯，Immunovant Inc公布2025财年Q4业绩，公司Q4营收0.00亿美元，同比持平，归母净利润亏损1.11亿美元，同比亏损缩窄0.4%。
02-06 20:52
财报速睇 | Immunovant Inc 2025财年Q4营收0.00亿美元，同比下降0.0%；归母净利润亏损1.11亿美元，同比亏损缩窄0.4%
华盛资讯2月6日讯，Immunovant Inc公布2025财年Q4业绩，公司Q4营收0.00亿美元，同比下降0.0%，归母净利润亏损1.11亿美元，同比亏损缩窄0.4%。
02-06 20:35
Immunovant Q3 EPS $(0.61) Beats $(0.71) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.71) by 13.72 percent. This is a 19.74 percent increase over losses of $(0.76) per share from the
02-06 20:02
Immunovant Q3 Earnings Assessment
Immunovant (NASDAQ:IMVT) announced its Q3 earnings on Friday, February 6, 2026 ...
02-06 20:02
Earnings Scheduled For February 6, 2026
Companies Reporting Before The Bell • Biogen (NASDAQ:BIIB) is estimated to repo...
02-06 19:11
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up
Insiders have been trading these 5 stocks: (($APLS)), (($OLMA)), (($XCUR)), (($...
01-24 21:01
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Immunovant will report its third-quarter 2025 financial results and provide a business update on February 6, 2026, at 8:00 a.m. ET. Interested parties can access the conference call via the provided registration link or under “News & Events” on Immunovant’s investor website. The webcast will be archived for later access. Immunovant, a clinical-stage immunology company, focuses on developing innovative therapies for autoimmune diseases using anti-...
01-23 22:25
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
